{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:54:51Z","timestamp":1789743291930,"version":"4.0.1"},"reference-count":104,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004263","name":"FAPERGS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004263","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Brazilian Research Funding Agencies"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.vaccine.2017.08.067","type":"journal-article","created":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T13:15:21Z","timestamp":1504530921000},"page":"5559-5567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["DNA vaccines against leptospirosis: A literature review"],"prefix":"10.1016","volume":"35","author":[{"given":"Marcelle Moura","family":"Silveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tha\u00eds Larr\u00e9","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Andrade","family":"Schuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan John Alexander","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odir Ant\u00f4nio","family":"Dellagostin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiane Drawanz","family":"Hartwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.08.067_b0005","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00284-013-0505-4","article-title":"Mannosylated LigANI produced in Pichia pastoris protects hamsters against leptospirosis","volume":"68","author":"Hartwig","year":"2014","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0010","doi-asserted-by":"crossref","first-page":"e0133720","DOI":"10.1371\/journal.pone.0133720","article-title":"Leptospirosis in Mexico: epidemiology and potential distribution of human cases","volume":"10","author":"Sanchez-Montes","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.08.067_b0015","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/CVI.00034-13","article-title":"A prime-boost strategy using the novel vaccine candidate, LemA, protects hamsters against leptospirosis","volume":"20","author":"Hartwig","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0020","doi-asserted-by":"crossref","first-page":"e0004122","DOI":"10.1371\/journal.pntd.0004122","article-title":"Global burden of leptospirosis: estimated in terms of disability adjusted life years","volume":"9","author":"Torgerson","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.08.067_b0025","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1017\/S0950268815000515","article-title":"Prevalence and risk factors for Leptospira exposure in New Zealand veterinarians","volume":"143","author":"Sanhueza","year":"2015","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2017.08.067_b0030","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1590\/0074-02760140276","article-title":"The use of halloysite clay and carboxyl-functionalised multi-walled carbon nanotubes for recombinant LipL32 antigen delivery enhanced the IgG response","volume":"110","author":"Hartwig","year":"2015","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.vaccine.2017.08.067_b0035","doi-asserted-by":"crossref","first-page":"e0129236","DOI":"10.1371\/journal.pone.0129236","article-title":"Diagnosis of leptospirosis: comparison between microscopic agglutination test, IgM-ELISA and IgM rapid immunochromatography Test","volume":"10","author":"Niloofa","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.08.067_b0040","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cimid.2007.05.003","article-title":"Current status of leptospirosis in Japan and Philippines","volume":"30","author":"Yanagihara","year":"2007","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.067_b0045","first-page":"249","article-title":"Efficacy and safety of a vaccine against human leptospirosis in Cuba","volume":"15","author":"Martinez","year":"2004","journal-title":"Rev Panam Salud Publica"},{"key":"10.1016\/j.vaccine.2017.08.067_b0050","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1469-0691.2007.01662.x","article-title":"Safety and immunogenicity of subcutaneous or intramuscular administration of a monovalent inactivated vaccine against Leptospira interrogans serogroup Icterohaemorrhagiae in healthy volunteers","volume":"13","author":"Laurichesse","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2017.08.067_b0055","first-page":"224","article-title":"An evaluation of the serological and epidemiological effects of the outer envelope vaccine to Leptospira","volume":"66","author":"Yan","year":"2003","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.vaccine.2017.08.067_b0060","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/01.qco.0000178824.05715.2c","article-title":"Leptospirosis","volume":"18","author":"McBride","year":"2005","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.067_b0065","unstructured":"FAINE SBA, B.; BOLIN, C. e PEROLAT, P. Leptospira and leptospirosis. Melbourne, Australia: MediSci; 1999."},{"key":"10.1016\/j.vaccine.2017.08.067_b0070","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3390\/pharmaceutics6030378","article-title":"Intranasal DNA vaccine for protection against respiratory infectious diseases: the delivery perspectives","volume":"6","author":"Xu","year":"2014","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.vaccine.2017.08.067_b0075","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv008","article-title":"A KALA-modified lipid nanoparticle containing CpG-free plasmid DNA as a potential DNA vaccine carrier for antigen presentation and as an immune-stimulative adjuvant","author":"Miura","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2017.08.067_b0080","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1007\/s00253-012-4403-7","article-title":"Improving the safety of viral DNA vaccines: development of vectors containing both 5\u2032 and 3\u2032 homologous regulatory sequences from non-viral origin","volume":"97","author":"Martinez-Lopez","year":"2013","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0085","doi-asserted-by":"crossref","first-page":"e0139671","DOI":"10.1371\/journal.pone.0139671","article-title":"Enhanced Immune Response to DNA vaccine encoding Bacillus anthracis PA-D4 protects mice against anthrax spore challenge","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.08.067_b0090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1297-9716-45-21","article-title":"Strategies and hurdles using DNA vaccines to fish","volume":"45","author":"Holvold","year":"2014","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2017.08.067_b0095","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.4161\/hv.25893","article-title":"DNA vaccines: a simple DNA sensing matter?","volume":"9","author":"Coban","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.08.067_b0100","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1586\/erv.13.33","article-title":"Synthetic DNA vaccine strategies against persistent viral infections","volume":"12","author":"Villarreal","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.08.067_b0105","first-page":"223","article-title":"Host response to Leptospira infection","volume":"387","author":"Zuerner","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0110","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/86354","article-title":"Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism","volume":"2","author":"Werts","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0115","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.4049\/jimmunol.175.9.6022","article-title":"Differential TLR recognition of leptospiral lipid A and lipopolysaccharide in murine and human cells","volume":"175","author":"Nahori","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0120","first-page":"139","article-title":"The molecular basis of leptospiral pathogenesis","volume":"387","author":"Murray","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0125","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/infdis\/jit569","article-title":"Immune evasion by pathogenic Leptospira strains: the secretion of proteases that directly cleave complement proteins","volume":"209","author":"Fraga","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.067_b0130","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrmicro2208","article-title":"Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen","volume":"7","author":"Ko","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0135","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-3083.2010.02505.x","article-title":"Leptospirosis: aspects of innate immunity, immunopathogenesis and immune evasion from the complement system","volume":"73","author":"Fraga","year":"2011","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0140","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/j.1462-5822.2011.01660.x","article-title":"Characteristic features of intracellular pathogenic Leptospira in infected murine macrophages","volume":"13","author":"Toma","year":"2011","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0145","doi-asserted-by":"crossref","first-page":"6926","DOI":"10.1128\/IAI.70.12.6926-6932.2002","article-title":"Rapid translocation of polarized MDCK cell monolayers by Leptospira interrogans, an invasive but nonintracellular pathogen","volume":"70","author":"Barocchi","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.08.067_b0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1128\/IAI.17.1.67-72.1977","article-title":"Host immunological mechanisms in the resistance of mice to leptospiral infections","volume":"17","author":"Adler","year":"1977","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.08.067_b0155","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1016\/j.vaccine.2011.02.084","article-title":"Recombinant LipL32 and LigA from Leptospira are unable to stimulate protective immunity against leptospirosis in the hamster model","volume":"29","author":"Lucas","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.067_b0160","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.vaccine.2012.11.028","article-title":"Evaluation of 238 antigens of Leptospira borgpetersenii serovar Hardjo for protection against kidney colonisation","volume":"31","author":"Murray","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.067_b0165","doi-asserted-by":"crossref","first-page":"e0142821","DOI":"10.1371\/journal.pone.0142821","article-title":"Evaluation of the Leptospira interrogans outer membrane protein OmpL37 as a vaccine candidate","volume":"10","author":"Oliveira","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.08.067_b0170","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/IAI.70.11.6147-6157.2002","article-title":"Evaluation of type 1 immune response in naive and vaccinated animals following challenge with Leptospira borgpetersenii serovar Hardjo: involvement of WC1(+) gammadelta and CD4 T cells","volume":"70","author":"Naiman","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.08.067_b0175","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1128\/CVI.00288-10","article-title":"A Leptospira borgpetersenii serovar Hardjo vaccine induces a Th1 response, activates NK cells, and reduces renal colonization","volume":"18","author":"Zuerner","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0180","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.4049\/jimmunol.0900506","article-title":"TLR4- and TLR2-mediated B cell responses control the clearance of the bacterial pathogen Leptospira interrogans","volume":"183","author":"Chassin","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0185","doi-asserted-by":"crossref","first-page":"e778","DOI":"10.1371\/journal.pntd.0000778","article-title":"Cross-reactivity of antibodies against leptospiral recurrent uveitis-associated proteins A and B (LruA and LruB) with eye proteins","volume":"4","author":"Verma","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.08.067_b0190","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1590\/S0100-879X2009005000013","article-title":"Immune strategies using single-component LipL32 and multi-component recombinant LipL32-41-OmpL1 vaccines against Leptospira","volume":"42","author":"Feng","year":"2009","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.vaccine.2017.08.067_b0195","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1590\/0074-02760150222","article-title":"DNA prime-protein boost based vaccination with a conserved region of leptospiral immunoglobulin-like A and B proteins enhances protection against leptospirosis","volume":"110","author":"Forster","year":"2015","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.vaccine.2017.08.067_b0200","first-page":"129","article-title":"Leptospiral extracellular matrix adhesins as mediators of pathogen-host interactions","author":"Vieira","year":"2013","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.vaccine.2017.08.067_b0205","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0024-3205(96)00502-4","article-title":"DNA vaccines","volume":"60","author":"Donnelly","year":"1997","journal-title":"Life Sci"},{"key":"10.1016\/j.vaccine.2017.08.067_b0210","first-page":"71","article-title":"DNA immunization as an efficient strategy for vaccination","volume":"1","author":"Bolhassani","year":"2009","journal-title":"Avicenna J Med Biotechnol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0215","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time?","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.vaccine.2017.08.067_b0220","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1093\/nar\/9.20.5233","article-title":"Possible role of flanking nucleotides in recognition of the AUG initiator codon by eukaryotic ribosomes","volume":"9","author":"Kozak","year":"1981","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2017.08.067_b0225","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1080\/21645515.2015.1047117","article-title":"Immunogenicity of a novel enhanced consensus DNA vaccine encoding the leptospiral protein LipL45","volume":"11","author":"Vijayachari","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.08.067_b0230","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s12033-014-9769-6","article-title":"Optimization of the immunogenicity of a DNA vaccine encoding a bacterial outer membrane lipoprotein","volume":"56","author":"Buaklin","year":"2014","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0235","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.vaccine.2007.10.029","article-title":"Evaluation of protective immunity of Leptospira immunoglobulin like protein A (LigA) DNA vaccine against challenge in hamsters","volume":"26","author":"Faisal","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.067_b0240","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.biotechadv.2009.02.003","article-title":"Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production","volume":"27","author":"Williams","year":"2009","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.vaccine.2017.08.067_b0245","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1089\/dna.1993.12.777","article-title":"Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors","volume":"12","author":"Montgomery","year":"1993","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0250","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1089\/hum.1996.7.10-1205","article-title":"An improved plasmid DNA expression vector for direct injection into skeletal muscle","volume":"7","author":"Hartikka","year":"1996","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2017.08.067_b0255","doi-asserted-by":"crossref","first-page":"e83246","DOI":"10.1371\/journal.pone.0083246","article-title":"LipL41, a hemin binding protein from Leptospira santarosai serovar Shermani","volume":"8","author":"Lin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.08.067_b0260","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.4161\/hv.7.11.17944","article-title":"Recombinant vaccines against leptospirosis","volume":"7","author":"Dellagostin","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2017.08.067_b0265","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1128\/IAI.70.9.4936-4945.2002","article-title":"Characterization of the leptospiral outer membrane and description of three novel leptospiral membrane proteins","volume":"70","author":"Haake","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.08.067_b0270","doi-asserted-by":"crossref","first-page":"592858","DOI":"10.1155\/2014\/592858","article-title":"Production and characterization of a polyclonal antibody of anti-rLipL21-IgG against Leptospira for early detection of acute leptospirosis","volume":"2014","author":"Seenichamy","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.vaccine.2017.08.067_b0275","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1128\/IAI.00531-13","article-title":"Leptospiral outer membrane protein LipL41 is not essential for acute leptospirosis but requires a small chaperone protein, lep, for stable expression","volume":"81","author":"King","year":"2013","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.08.067_b0280","doi-asserted-by":"crossref","first-page":"e51025","DOI":"10.1371\/journal.pone.0051025","article-title":"LipL32 Is a subsurface lipoprotein of Leptospira interrogans: presentation of new data and reevaluation of previous studies","volume":"8","author":"Pinne","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.08.067_b0285","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/1574-6968.12349","article-title":"Leptospiral extracellular matrix adhesins as mediators of pathogen-host interactions","volume":"352","author":"Vieira","year":"2014","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.vaccine.2017.08.067_b0290","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1128\/CVI.05720-11","article-title":"Protection against lethal leptospirosis after vaccination with LipL32 coupled or coadministered with the B subunit of Escherichia coli heat-labile enterotoxin","volume":"19","author":"Grassmann","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0295","doi-asserted-by":"crossref","first-page":"e0003712","DOI":"10.1371\/journal.pntd.0003712","article-title":"Evaluation of cell binding activities of Leptospira ECM adhesins","volume":"9","author":"Robbins","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.08.067_b0300","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1128\/IAI.73.7.4062-4069.2005","article-title":"Protection against Leptospira interrogans sensu lato challenge by DNA immunization with the gene encoding hemolysin-associated protein 1","volume":"73","author":"Branger","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.08.067_b0305","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1016\/j.vaccine.2007.05.053","article-title":"The terminal portion of leptospiral immunoglobulin-like protein LigA confers protective immunity against lethal infection in the hamster model of leptospirosis","volume":"25","author":"Silva","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.067_b0310","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1128\/CVI.00601-12","article-title":"A conserved region of leptospiral immunoglobulin-like A and B proteins as a DNA vaccine elicits a prophylactic immune response against leptospirosis","volume":"20","author":"Forster","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0315","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1128\/IAI.01635-06","article-title":"Physiological osmotic induction of Leptospira interrogans adhesion: LigA and LigB bind extracellular matrix proteins and fibrinogen","volume":"75","author":"Choy","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.08.067_b0320","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1128\/IAI.00474-12","article-title":"OmpL1 is an extracellular matrix- and plasminogen-interacting protein of Leptospira spp","volume":"80","author":"Fernandes","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.08.067_b0325","first-page":"75","article-title":"OmpL1 DNA vaccine cross-protects against heterologous Leptospira spp. challenge","volume":"25","author":"Maneewatch","year":"2007","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0330","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1128\/IAI.73.8.4853-4863.2005","article-title":"Surfaceome of Leptospira spp","volume":"73","author":"Cullen","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.08.067_b0335","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1128\/IAI.74.3.1745-1750.2006","article-title":"Immunoprotection of recombinant leptospiral immunoglobulin-like protein A against Leptospira interrogans serovar Pomona infection","volume":"74","author":"Palaniappan","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.08.067_b0340","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1128\/IAI.71.5.2414-2421.2003","article-title":"LipL21 is a novel surface-exposed lipoprotein of pathogenic Leptospira species","volume":"71","author":"Cullen","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.08.067_b0345","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/CVI.00405-09","article-title":"Identification of immunodominant B- and T-cell combined epitopes in outer membrane lipoproteins LipL32 and LipL21 of Leptospira interrogans","volume":"17","author":"Lin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0350","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/cmi.2008.48","article-title":"Protection of guinea pigs against Leptospira interrogans serovar Lai by LipL21 DNA vaccine","volume":"5","author":"He","year":"2008","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0355","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1371\/journal.ppat.0030097","article-title":"The OmpA-like protein Loa22 is essential for leptospiral virulence","volume":"3","author":"Ristow","year":"2007","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2017.08.067_b0360","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2217\/fmb.10.102","article-title":"Leptospira as an emerging pathogen: a review of its biology, pathogenesis and host immune responses","volume":"5","author":"Evangelista","year":"2010","journal-title":"Future Microbiol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0365","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1128\/IAI.00741-06","article-title":"Characterization of the outer membrane proteome of Leptospira interrogans expressed during acute lethal infection","volume":"75","author":"Nally","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.08.067_b0370","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4014\/jmb.1408.08007","article-title":"Immunogenicity of a DNA and recombinant protein vaccine combining LipL32 and Loa22 for leptospirosis using chitosan as a delivery system","volume":"25","author":"Umthong","year":"2015","journal-title":"J Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0375","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1128\/IAI.70.1.323-334.2002","article-title":"Novel 45-kilodalton leptospiral protein that is processed to a 31-kilodalton growth-phase-regulated peripheral membrane protein","volume":"70","author":"Matsunaga","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.08.067_b0380","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jprot.2014.08.015","article-title":"Comparative subproteome analysis of three representative Leptospira interrogans vaccine strains reveals cross-reactive antigens and novel virulence determinants","volume":"112","author":"Zeng","year":"2015","journal-title":"J Proteomics"},{"key":"10.1016\/j.vaccine.2017.08.067_b0385","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.molcel.2010.11.020","article-title":"Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma","volume":"40","author":"Levy","year":"2010","journal-title":"Mol Cell"},{"key":"10.1016\/j.vaccine.2017.08.067_b0390","doi-asserted-by":"crossref","first-page":"6372","DOI":"10.1128\/AEM.00911-12","article-title":"Differential in vivo gene expression of major Leptospira proteins in resistant or susceptible animal models","volume":"78","author":"Matsui","year":"2012","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0395","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/erv.11.188","article-title":"Technologies for enhanced efficacy of DNA vaccines","volume":"11","author":"Saade","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.08.067_b0400","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fimmu.2013.00114","article-title":"Mechanisms of action of adjuvants","volume":"4","author":"Awate","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0405","doi-asserted-by":"crossref","first-page":"e0145637","DOI":"10.1371\/journal.pone.0145637","article-title":"HIV envelope trimer specific immune response is influenced by different adjuvant formulations and heterologous prime-boost","volume":"11","author":"Apostolico Jde","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.08.067_b0410","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.3892\/mmr.2015.3950","article-title":"Chitosan as an adjuvant for a Helicobacter pylori therapeutic vaccine","volume":"12","author":"Gong","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.vaccine.2017.08.067_b0415","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12951-015-0146-9","article-title":"Chitosan functionalisation of gold nanoparticles encourages particle uptake and induces cytotoxicity and pro-inflammatory conditions in phagocytic cells, as well as enhancing particle interactions with serum components","volume":"13","author":"Boyles","year":"2015","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.vaccine.2017.08.067_b0420","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/icb.2014.21","article-title":"Activation of the NLRP3 inflammasome is not a feature of all particulate vaccine adjuvants","volume":"92","author":"Neumann","year":"2014","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0425","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-065X.2011.01046.x","article-title":"The inflammasome: an integrated view","volume":"243","author":"Gross","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2017.08.067_b0430","doi-asserted-by":"crossref","first-page":"13463","DOI":"10.1073\/pnas.0906988106","article-title":"IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells","volume":"106","author":"Guo","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.08.067_b0435","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.vaccine.2014.10.078","article-title":"Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination","volume":"33","author":"Leroux-Roels","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.067_b0440","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1939-1676.2003.tb02448.x","article-title":"Adjuvants in veterinary vaccines: modes of action and adverse effects","volume":"17","author":"Spickler","year":"2003","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.vaccine.2017.08.067_b0445","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1080\/21645515.2016.1154247","article-title":"Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine","volume":"12","author":"Fochesato","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.08.067_b0450","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.08.067_b0455","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0460","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.4049\/jimmunol.1600817","article-title":"The Lymphatic Immune Response Induced by the Adjuvant AS01: A Comparison of Intramuscular and Subcutaneous Immunization Routes","volume":"197","author":"Neeland","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0465","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2017.08.067_b0470","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/NEN.0b013e3181d5d053","article-title":"Induction of progressive demyelinating autoimmune encephalomyelitis in common marmoset monkeys using MOG34-56 peptide in incomplete freund adjuvant","volume":"69","author":"Jagessar","year":"2010","journal-title":"J Neuropathol Exp Neurol"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2017.08.067_b0475","article-title":"The use of oil adjuvants in therapeutic vaccines","volume":"24","author":"Aucouturier","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.067_b0480","doi-asserted-by":"crossref","first-page":"e0136420","DOI":"10.1371\/journal.pone.0136420","article-title":"Inactivated enterovirus 71 vaccine produced by 200-L scale serum-Free microcarrier bioreactor system provides cross-protective efficacy in human SCARB2 transgenic mouse","volume":"10","author":"Wu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.08.067_b0485","doi-asserted-by":"crossref","first-page":"e101474","DOI":"10.1371\/journal.pone.0101474","article-title":"Alum and squalene-oil-in-water emulsion enhance the titer and avidity of anti-Abeta antibodies induced by multimeric protein antigen (1\u201311)E2, preserving the Igg1-skewed isotype distribution","volume":"9","author":"Mantile","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.08.067_b0490","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.4049\/jimmunol.1402071","article-title":"MF59 mediates its B cell adjuvanticity by promoting T follicular helper cells and thus germinal center responses in adult and early life","volume":"194","author":"Mastelic Gavillet","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0495","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.addr.2013.05.013","article-title":"Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant","volume":"65","author":"Hafner","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2017.08.067_b0500","doi-asserted-by":"crossref","first-page":"690438","DOI":"10.1155\/2010\/690438","article-title":"Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant","volume":"2010","author":"Jin","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.vaccine.2017.08.067_b0505","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1590\/S0100-879X2012007500142","article-title":"Recombinant vaccines and the development of new vaccine strategies","volume":"45","author":"Nascimento","year":"2012","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.vaccine.2017.08.067_b0510","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.067_b0515","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.vaccine.2015.11.043","article-title":"DNA vaccination of poultry: the current status in 2015","volume":"34","author":"Meunier","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.067_b0520","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1128\/JVI.02564-07","article-title":"Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation","volume":"82","author":"Liu","year":"2008","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17311659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17311659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T02:30:22Z","timestamp":1602901822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17311659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":104,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0264410X17311659"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.08.067","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA vaccines against leptospirosis: A literature review","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.08.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}